Lipid abnormalities in the nephrotic syndrome: The therapeutic role of statins

Journal of Nephrology

Volumn 14, Issue 4 SUPPL., 2001, Pages

  Wheeler, David C ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cardiovascular disease; Cholesterol; HMG CoA reductase inhibitor; Hyperlipidaemia; Proteinuria

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ANIMAL; BLOOD; DISEASE COURSE; GLOMERULUS; HUMAN; HYPERLIPIDEMIA; KIDNEY DISEASE; NEPHROTIC SYNDROME; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; ANTILIPEMIC AGENTS; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; KIDNEY DISEASES; KIDNEY GLOMERULUS; LIPIDS; NEPHROTIC SYNDROME;

EID: 0035522915     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: Causes, consequences, and treatment. Am J Kidney Dis 1994; 23: 331-46.
2. Radhakrishnan J, Appel AS, Valeri A, Appel GB. The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis 1993; 22: 135-42.